Outlook TherapeuticsOTLK +6.21%11 FCF Yield % is -18.30 as of Jun. 28, 2026. GuruFocus rates OTLK with a GF Score™ of 11/100. The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Outlook Therapeutics ranks worse than 64.48% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Outlook Therapeutics FCF Yield % Related Terms
Outlook Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Outlook Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (OTLK) has a FCF Yield % of -18.30 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #913 out of 1416 companies in the Biotechnology industry, placing it in the top 64.5%.
Is Outlook Therapeutics' FCF Yield % too high?
Outlook Therapeutics' current FCF Yield % is -18.30. Based on the distribution chart, Outlook Therapeutics ranks #913 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' FCF Yield % compare to INO and CBUS?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #913 out of 1416 companies for FCF Yield %. This places Outlook Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current FCF Yield % is -18.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (OTLK) has a current FCF Yield % of -18.30. The current FCF Yield % is -18.30. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Outlook Therapeutics (OTLK), the current FCF Yield % is -18.30 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score
Get the complete analysis for OTLK
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLK has been successfully added to your 
